Program

Timetable

Timetable

President's Lecture

November 18 (Wed.) 16:20-16:40 Room A (2F Leo Esaki Main Convention Hall)

  • ChairTakafumi Komori
  • Biopharmaceutical Assessment, Deep Human Biology Learning, Eisai Co., Ltd.
  • PLMessage from the president (Tentative)
  • SpeakerHiroyuki Kusuhara
  • Graduate School of Pharmaceutical Sciences, The University of Tokyo

Short Course/Annual Meeting Joint Distinguished Lecture

November 16 (Mon.) 17:30-18:30 Room A (2F Leo Esaki Main Convention Hall)

  • ChairTakafumi Komori
  • Biopharmaceutical Assessment, Deep Human Biology Learning, Eisai Co., Ltd.
  • ChairRyoichi Saito
  • Research Division, Chugai Pharmaceutical Co., Ltd.
  • JDLIntegration of Molecular Simulation and Artificial Intelligence for Drug Molecule Discovery and Design (Tentative)
  • SpeakerTakatsugu Hirokawa
  • Division of Biomedical Science, Institute of Medicine, University of Tsukuba

Special Invited lecture 1

November 17 (Tue.) 13:00-14:00 Room A (2F Leo Esaki Main Convention Hall)

ISSX M&S – JSSX M&SP Collaborative Initiative　ICH M15 in Action: Industrial Case Studies in Model-Informed Drug Development (MIDD)

  • ChairChie Emoto
  • Translational Research Division, Chugai Pharmaceutical Co., Ltd.
  • ChairTeruki Hamada
  • Translational Research Business Unit, Axcelead Drug Discovery Partners, Inc.
  • SIL1-1The Road to Tsukuba: How ISSX and JSSX Got Here
  • SpeakerChie Emoto
  • Translational Research Division, Chugai Pharmaceutical Co., Ltd.
  • SIL1-2ICH M15 MIDD in Practice: PBPK for DDI assessment in the Development of GLP-1 Therapeutics
  • SpeakerJenny Y. Chien
  • Eli Lilly and Company

Special Invited lecture 2

November 18 (Wed.) 13:40-14:40 Room A (2F Leo Esaki Main Convention Hall)

  • ChairKazuhiro Tetsuka
  • Translational & Biomedical Science, Astellas Pharma Inc.
  • SIL2Microengineered mimicry of human health and disease
  • SpeakerDan Huh
  • University of Pennsylvania

Special Invited lecture 3

November 18 (Wed.) 16:40-17:10 Room A (2F Leo Esaki Main Convention Hall)

  • ChairHiroshi Yamazaki
  • Showa Pharmaceutical University
  • SIL3Implications of CYP2J2 in drug-induced cardiac adverse effects
  • SpeakerEric Chan
  • Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore

Symposium 1 (Modeling & Systems Pharmacology DIS)

November 17 (Tue.) 9:30-11:30 Room A (2F Leo Esaki Main Convention Hall)

Cutting-Edge Research on Mechanistic Absorption Modeling

  • ChairShinichi Kijima
  • Pharmaceuticals and Medical Devices Agency
  • ChairChie Emoto
  • Translational Research Division, Chugai Pharmaceutical Co., Ltd.
  • SY1-1PBBM Applications in Drug Development (Tentative)
  • SpeakerTycho Heimbach
  • MSD
  • ChairSatoshi Nakayama
  • DMPK Research Laboratories, Research Division, Tanabe Pharma Corporation
  • ChairHiroyuki Sayama
  • Modeling & Simulation, Early Development & Translational Science, Astellas Pharma Inc.
  • SY1-2Predicting negative food effect on oral drug absorption using physiologically based pharmacokinetic modeling (Tentative)
  • SpeakerAyahisa Watanabe
  • Laboratory for Medicinal Chemistry Research, Pharmaceutical Research Division, Shionogi & Co., Ltd.
  • ChairYoshinobu Nakamaru
  • Clinical Pharmacology Strategy, Clinical Development, R&D Japan, Bristol-Myers Squibb K.K.
  • ChairTakashi Yoshikado
  • Laboratory of Clinical Pharmacology, Yokohama University of Pharmacy
  • SY1-3Prediction of food effect on oral drug absorption: an overveiw
  • SpeakerKiyohiko Sugano
  • College of Pharmaceutical Science, Ritsumeikan University
  • ChairRyoko Sawamura
  • Quantitative Clinical Pharmacology Department, Daiichi Sankyo Co., Ltd.
  • ChairTsuyoshi Minematsu
  • Formulation & ADME, Oncology Research, Astellas Pharma Inc.
  • SY1-4A PBPK Framework for Naïve Predictions of Monoclonal Antibody Pharmacokinetics After Subcutaneous Administration
  • SpeakerDonato Teutonico
  • Pharmacometrics, Translational Medicine Unit, Sanofi, Vitry-sur- Seine, France
  • Panel Discussion
  • ChairYuki Iwaki
  • Clinical Pharmacology & Pharmacometrics, Global R&D, Johnson & Johnson
  • ChairTeruki Hamada
  • Translational Research Business Unit, Axcelead Drug Discovery Partners, Inc.

Symposium 2 (Metabolism/Toxicity DIS-1)

November 17 (Tue.) 9:30-11:30 Room B (2F Convention Hall 200)

How to teach drug metabolism and pharmacokinetics: Bridging academic lectures, practical training, and industry education

  • ChairSeigo Sanoh
  • School of Pharmaceutical Sciences, Wakayama Medical University
  • ChairKota Kato
  • Applied Safety-JP, Applied Research & Nonclinical Safety, Early Development & Translational Science, Astellas Pharma Inc.
  • SY2-1Drug metabolism education in school of pharmacy and pharmaceutical sciences (Tentative)
  • SpeakerKouichi Yoshinari
  • Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka
  • SY2-2Education and Research on Species Differences in Drug Metabolism and Pharmacokinetics (Tentative)
  • SpeakerShouta Nakayama
  • Laboratory of Toxicology, Faculty of Veterinary Medicine, Hokkaido University
  • SY2-3Case Studies and Future Perspectives on the Development of DMPK Scientists in Pharmaceutical Companies
  • SpeakerSatoshi Kitamura
  • Applied Research & Nonclinical Safety, Early Development & Translational Science, Astellas Pharma Inc.
  • SY2-4Educational programs for researchers in SNBL - From newcomer to senior researcher
  • SpeakerKazuhiro Nishimiya
  • Shin Nippon Biomedical Laboratories, Ltd.
  • Panel Discussion

Symposium 3 (DDS DIS)

November 17 (Tue.) 9:30-11:30 Room E (1F Conference Room 102)

Frontiers in DDS research Opening New Avenues for the treatment of CNS Disorders

  • ChairTakanori Kanazawa
  • Graduate School of Biomedical Sciences, Tokushima University
  • ChairHidefumi Mukai
  • Department of Pharmaceutical Informatics, Graduate School of Biomedical Sciences, Nagasaki University
  • SY3-1Development of Intranasal Drug Delivery Systems and Their Pharmacokinetic Evaluation for Therapeutic Application in Central Nervous System Disorders
  • SpeakerAkiko Tanaka
  • Laboratory of Pharmaceutical Technology, Kobe Pharmaceutical University
  • SY3-2Brain-targeted drug delivery using ultrasound and micro/nanobubbles
  • SpeakerDaiki Omata
  • Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • SY3-3Hippocampal neuron-targeted delivery of biopharmaceuticals for enhancing their therapeutic potential against dementia
  • SpeakerNoriyasu Kamei
  • Laboratory of Drug Delivery Systems, Faculty of Pharmaceutical Sciences, Kobe Gakuin University
  • SY3-4Development of a novel targeted DDS for the treatment of neuroimmune disorders
  • SpeakerKosuke Shimizu
  • Nanotheranostics Laboratory, Institute of Photonics Medicine, Hamamatsu University School of Medicine
  • SY3-5Dynamic nanomedicine for brain targeting
  • SpeakerKanjiro Miyata
  • Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo

Symposium 4 (Dynamic education and cross-disciplinary DIS)

November 17 (Tue.) 14:15-16:45 Room B (2F Convention Hall 200)

Basic course of pharmacokinetics on cross-disciplinary

  • ChairSeigo Sanoh
  • School of Pharmaceutical Sciences, Wakayama Medical University
  • ChairTomomi Furihata
  • Laboratory of Advanced Drug Development Sciences, Tokyo University of Pharmacy and Life Sciences
  • SY4-1Utilizing human intestinal cells for the prediction of the risk of drug-induced intestinal toxicity
  • SpeakerKazuya Maeda
  • Laboratory of Pharmaceutics, School of Pharmacy, Kitasato University
  • SY4-2Physiologically Based Biopharmaceutics Modeling (PBBM): Fundamentals and Future Perspectives
  • SpeakerAtsushi Kambayashi
  • Faculty of Pharmaceutical Sciences, Tokyo University of Science
  • SY4-3Volume of distribution prediction based on in silico predicted values
  • SpeakerToshiki Arai
  • Drug Metabolism and Pharmacokinetics Research Department, Nippon Shinyaku Co.,Ltd./Faculty of Pharmacy, Kanazawa University
  • SY4-4Fundamentals and applications of cell-based assays using iPS cell-derived cells
  • SpeakerHiroshi Kato
  • Toyama Research Development Center, FUJIFILM Toyama Chemical Co., Ltd.
  • SY4-5Bioanalysis of ADCs Using Immuno-Affinity LC/MS Technology
  • SpeakerToshiko Yahata
  • Formulation/ADME, Oncology Research, Astellas Pharma Inc.

Symposium 5 (Analysis & Imaging DIS)

November 17 (Tue.) 14:15-16:45 Room E (1F Conference Room 102)

Spatial Omics Driving the Next Generation of Pharmacokinetics ― A New Paradigm in Spatially Resolved Pharmacokinetics ―

  • ChairYukari Tanaka
  • DMPK and Analytical Sciences 4 group, Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd.
  • ChairMasamitsu Maekawa
  • Department of Pharmaceutical Sciences, Tohoku University Hospital
  • SY5-1Histopathology-Guided Spatial Analysis in Cancer: Insights from Multiplex IHC and Spatial Transcriptomics
  • SpeakerMaki Kobayashi
  • Translational Research Laboratories, Precision Medicine Function, Daiichi Sankyo Co., Ltd.
  • SY5-2Development of AI-Assisted Proteomics for Pathology Specimens
  • SpeakerYasuo Uchida
  • Laboratory of Molecular Systems Pharmaceutics, Graduate School of Biomedical and Health Sciences, Hiroshima University
  • SY5-3Elementomics analysis and PET/SPECT metallomics-driven drug discovery research
  • SpeakerHiroyuki Yasui
  • Department of Analytical and Bioinorganic Chemistry, Division of Analytical and Physical Sciences, Kyoto Pharmaceutical University
  • SY5-4Exploration of prognostic markers for renal function decline by spatial transcriptome analysis (tentative)
  • SpeakerKazuhiro Morishita
  • Biological Technology Dept., Research Division, Chugai Pharmaceutical Co., Ltd.
  • SY5-5Spatial lipidomics to illuminate the lipidome signatures associated with biology and disease
  • SpeakerMakoto Arita
  • Faculty of Pharmacy, Keio University/RIKEN-IMS

Symposium 6 (Regulation DIS)

November 18 (Wed.) 9:30-12:00 Room A (2F Leo Esaki Main Convention Hall)

Current and Future Regulation on New Approach Methodologies

  • ChairSatoshi Kitamura
  • Applied Research & Nonclinical Safety, Early Development & Translational Science, Astellas Pharma Inc.
  • ChairYoshiro Saito
  • National Institute of Health Sciences
  • SY6-1International Trends in NAMs in Nonclinical Evaluation and PMDA’s Initiatives to Promote the 3Rs (tentative)
  • SpeakerFumito Mikashima
  • Pharmaceuticals and Medical Devices Agency
  • SY6-2Drug Development Tool Qualification and Integration at FDA: Innovative Science and Technology Approach for New Drugs (ISTAND) Program (tentative)
  • SpeakerYork Tomita
  • CDER-Office of New Drugs, US FDA
  • SY6-3Current trends and challenges of using NAMs in the nonclinical evaluation of therapeutic monoclonal antibodies (tentative)
  • SpeakerAkiko Ishii-Watabe
  • Div. Biological Chemistry and Biologicals, National Institute of Health Sciences
  • SY6-4Development of Novel Biodistribution Assessment Technologies for Biologics (tentative)
  • SpeakerMiho Nagayasu
  • Translational Research Division, Chugai Pharmaceutical Co., Ltd.
  • SY6-5Regulatory Use of Microphysiological Systems (MPS): Efforts Toward Establishing OECD Test Guidelines (tentative)
  • SpeakerSeiichi Ishida
  • Dept. Biotechnology and Life Science, Sojo University

Symposium 7
(AI/Machine Learning for Pharmacokinetic Prediction DIS)

November 18 (Wed.) 9:30-12:00 Room B (2F Convention Hall 200)

DMPK Meets the AI/ML Frontier: A Gateway Through M&S and DDI

  • SY7-1Progress Report on DIS AI/ML-based PK Prediction
  • SpeakerYohei Kosugi
  • Drug Metabolism, Pharmacokinetics and Modeling, Preclinical and Translational Sciences, Takeda Pharmaceutical Company Limited
  • ChairKoichi Handa
  • Pharmacokinetics Laboratory, Non-clinical Development Department, Research & Development Division, Meiji Seika Pharma, Co., Ltd.
  • ChairHiroaki Iwata
  • Faculty of Medicine, Tottori University
  • SY7-2Applying Machine Learning to PBPK Models: Significance and Practical Challenges in DMPK Research
  • SpeakerShinji Nakayama
  • DMPK Research Laboratories, Research Division, Tanabe Pharma Corporation
  • SY7-3Prediction of Pharmacokinetic Parameters by Machine Learning Utilizing Biomimetic Chromatography
  • SpeakerHideaki Mamada
  • DMPK Research Laboratories, Central Pharmaceutical Research Institute, Shionogi &Co., Ltd.
  • SY7-4OrchestRA: Democratizing Data-Driven Drug Discovery with an Autonomous Multi-AI Agent System
  • SpeakerKazuki Nakanishi
  • Department of AI Systems Medicine, M&D Data Science Center, Institute of Integrated Research, Institute of Science Tokyo
  • SpeakerHideyuki Shimizu
  • Graduate School of Medical and Dental Sciences, Institute of Science Tokyo
  • ChairTadahaya Mizuno
  • Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo
  • ChairYohei Kosugi
  • Drug Metabolism, Pharmacokinetics and Modeling, Preclinical and Translational Sciences, Takeda Pharmaceutical Company Limited
  • SY7-5Initiatives in Drug Discovery AI/ML at Daiichi Sankyo (Tentative)
  • SpeakerShotaro Maedera
  • Data Intelligence CoE, Global DX, Daiichi Sankyo Co., Ltd.
  • SY7-6Machine learning for drug discovery projects
  • SpeakerHiroshi Kajino
  • Axcelead Drug Discovery Partners, Inc.
  • Panel Discussion

Symposium 8 (New modality DIS)

November 18 (Wed.) 9:30-11:30 Room E (1F Conference Room 102)

Advances in Quantitative Technologies for New Modalities

  • ChairYoshiteru Kamiyama
  • Applied research and non-clinical safety, Applied Drug Metabolism and Pharmacokinetics, Astellas Pharma Inc.
  • ChairYoichi Naritomi
  • Kobe Research Institute, HEALIOS K.K.
  • SY8-1From GalNAc to Beyond the Liver: Clinical Implementation of RNAi Delivery and Expansion of Target Tissues (Tentative)
  • SpeakerSoichiro Matsushima
  • Clinical Development, Alnylam Japan K.K.
  • SY8-2Biodistribution profile of ASP2246 (mRNA-LNP) after intracerebral parenchymal administration in cynomolgus monkeys (Tentative)
  • SpeakerAkihiro Matsumoto
  • Applied research and non-clinical safety, Applied Drug Metabolism and Pharmacokinetics, Astellas Pharma Inc.
  • SY8-3Considerations for Biodistribution Assessment of Induced Pluripotent Stem Cell-derived Cell Therapy Products: A Case Study with Pancreatic Islet-like Cells
  • SpeakerMiyu Nakayama
  • Drug Metabolism & Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited
  • SY8-4Development of quantitative methods and characterization of in vivo pharmacokinetics of HLCN061, gene engineered human induced pluripotent stem cell-derived natural killer cells
  • SpeakerYoichi Naritomi
  • Kobe Research Institute, HEALIOS K.K.

Symposium 9 (Transporter DIS)

November 19 (Thu.) 9:30-12:00 Room A (2F Leo Esaki Main Convention Hall)

Diverse Approaches to Unraveling Transporter Functions

  • ChairTomoya Yasujima
  • Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University
  • ChairSaki Noguchi
  • Division of Pharmaceutics, Faculty of Pharmacy, Keio University
  • SY9-1Hidden Physiology of Transporters through a Multiscale Approach
  • SpeakerShushi Nagamori
  • Multiscale Nutritional Biochemistry, The Jikei University School of Medicine
  • SY9-2Development of Microphysiological Systems (MPS) Targeting Renal Proximal Tubule Transporters and Their Application to Drug Discovery
  • SpeakerRyuji Yokokawa
  • Department of Micro Engineering, Graduate School of Engineering, Kyoto University
  • SY9-3Species differences in placental transporters and their effects on fetal transfer
  • SpeakerMasatoshi Tomi
  • Division of Pharmaceutics, Faculty of Pharmacy, Keio University
  • SY9-4Drug repositioning targeting organic cation transporter 2 based on integrated analysis of machine learning and medical big data
  • SpeakerKenji Ikemura
  • Department of Pharmacy, The University of Osaka Hospital
  • SY9-5Identification and functional analysis of the SLC9C1-associated protein complex (Tentative)
  • SpeakerRie Iida
  • Department of Experimental Genome Research, Research Institute for Microbial Diseases, The University of Osaka
  • SY9-6Hepatic OATPs as conformational machines: integrating kinetics and structure (Tentative)
  • SpeakerShen Ling
  • ShanghaiTech University

Symposium 10 (Metabolism/Toxicity DIS-2)

November 19 (Thu.) 9:30-11:30 Room B (2F Convention Hall 200)

The future of drug metabolism and toxicology: Insights from emerging researchers

  • ChairKousei Ito
  • Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University
  • ChairTatsuki Fukami
  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University
  • SY10-1Transcriptional regulation of enzymes involved in drug response: roles of G-quadruplex structures and coordinated expression with transporters (Tentative)
  • SpeakerChieri Fujino
  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University
  • SY10-2Impact of oxygen environment control on hepatocyte functions in culture models — Improved hypoxia, enhanced drug metabolism, and induction of zonation-like phenotypes —
  • SpeakerNaoki Takaoka
  • Laboratory of Pharmaceutical Health Science, School of Pharmaceutical Sciences, Wakayama Medical University
  • SY10-3Pharmacokinetic study with highly humanized animal models
  • SpeakerGenki Minegishi
  • Department of Biopharmaceutics, Graduate School of Clinical Pharmacy, Meiji Pharmaceutical University
  • SY10-4Integrated Experimental and Data-Based Analysis of Immune Responses in Therapeutic Antibody Efficacy and Safety
  • SpeakerYuta Tamemoto
  • Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University
  • SY10-5Exploration of Endogenous Biomarkers for Early Detection of Drug-Induced Liver Injury
  • SpeakerMasaki Kumondai
  • Department of Pharmaceutical Sciences, Tohoku University Hospital

Symposium 11 (Microphysiological system and iPS DIS)

November 19 (Thu.) 9:30-11:30 Room D (1F Conference Room 101)

Next generation microrheological systems, models, and their application

  • ChairKengo Watanabe
  • Daiichi Sankyo Co., Ltd.
  • ChairSeiichi Ishida
  • Biotechnology and Life Science, Sojo University
  • SY11-1A Novel Evaluation Strategy for Drug-Induced Kidney Injury Incorporating Hepatic Metabolism: Toward Understanding Inter-Organ Crosstalk
  • SpeakerHiroshi Arakawa
  • Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Nagoya City University
  • SY11-2Science of human blood-brain barrier mimetics
  • SpeakerMasanori Tachikawa
  • Laboratory of Theoretical Chemistry for Drug Discovery, Graduate School of Biomedical Sciences, Tokushima University
  • SY11-3Strategies for the Implementation of Japan-Originated MPS　— Case Studies of Vascular and Renal Tubule Models —
  • SpeakerYoshikazu Kameda
  • R&D department, Physios Biotech, Inc.
  • SY11-4Pharmaceutical Industry Views on Next-Generation MPS for Pharmacology and Safety Evaluations in Drug Discovery and Future Directions
  • SpeakerMaho Okubo
  • Translational & Biomedical Science, Astellas Pharma Inc.

Symposium 12 (In vivo models DIS)

November 19 (Thu.) 13:30-15:30 Room B (2F Convention Hall 200)

Frontiers of in vivo Models Across Diverse Therapeutic Modalities: From Small Molecules to Regenerative Medicine

  • ChairKaoru Kobayashi
  • Laboratory of Biopharmaceutics, Meiji Pharmaceutical University
  • ChairSyunsuke Yamamoto
  • Discovery Biologics Dept., Chugai Pharmaceutical Co., Ltd.
  • SY12-1Research on Newt-type Dedifferentiation for Human Self-Regeneration (Tentative)
  • SpeakerChikafumi Chiba
  • University of Tsukuba
  • SY12-2Development of humanized liver mouse models for studying human drug metabolism and pharmacokinetics (Tentative)
  • SpeakerHiroshi Suemizu
  • Biomedical Research Division, Central Institute for Experimental Medicine and Life Science
  • SY12-3Development of a method for predicting human pharmacokinetics of targeted protein degraders using chimeric mice with humanized livers (Tentative)
  • SpeakerWeilin Shen
  • DMPK Research Laboratories, Research Division, Tanabe Pharma Corporation
  • SY12-4Prediction of human PK for Fc engineered antibodies with enhanced FcRn binding (Tentative)
  • SpeakerKenta Haraya
  • Discovery Biologics Dept., Chugai Pharmaceutical Co., Ltd.
  • SY12-5Key considerations in biodistribution evaluation of gene therapy products using adeno-associated virus vectors (Tentative)
  • SpeakerMiyu Nakayama
  • Drug Metabolism & Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited

Symposium 13 (Efficacy and Safety DIS)

November 19 (Thu.) 13:30-15:30 Room D (1F Conference Room 101)

Frontiers in Metabolism, Adverse Effects, and Toxicity Research for Next-Generation Drug Development

  • ChairMakoto Yamazaki
  • DMPK Research Laboratories, Research Division, Tanabe Pharma Corporation
  • ChairYuki Kishino
  • Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd.
  • ChairMasanori Tachikawa
  • Laboratory of Theoretical Chemistry for Drug Discovery, Graduate School of Biomedical Sciences, Tokushima University
  • SY13-1Targeting SPREDs for the Control of Refractory Inflammatory Diseases (Tentative)
  • SpeakerAi Kotani
  • Research Institute for Microbial Diseases, The University of Osaka
  • SY13-2Natural Language Processing–driven Extraction of Adverse Drug Reaction Information from Real-World Text and Its Applications (Tentative)
  • SpeakerSatoko Hori
  • Division of Drug Informatics, Faculty of Pharmaceutical Sciences, Keio University
  • SY13-3Challenge of unraveling the pathophysiological mechanisms of drug-induced interstitial lung disease (Tentative)
  • SpeakerKazuyoshi Kumagai
  • Medicinal Safety, Daiichi Sankyo Inc.
  • SY13-4Comparative study of acute CNS toxicity in rodents and non-human primates administered with centrally delivered antisense oligonucleotides (Tentative)
  • SpeakerHironobu Nishina
  • Safety Research Laboratories, Research Division, Tanabe Pharma Corporation
  • SY13-5Reconsidering the role of HLA in idiosyncratic drug toxicity (Tentative)
  • SpeakerShigeki Aoki
  • Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University

Symposium 14 (Absorption DIS)

November 19 (Thu.) 13:30-15:30 Room E (1F Conference Room 102)

Absorption Research EXPO2026: Romance and Adventure in Oral Absorption of Middle-to-Large Molecule Drugs

  • ChairYoshiyuki Shirasaka
  • Laboratory of Pharmaceutics, Showa Pharmaceutical University
  • ChairToshimichi Nakamura
  • Formulation & ADME, Oncology Research, Astellas Pharma Inc.
  • SY14-1Quantitative prediction of oral absorption of mid-size peptides: Proposing a new methodology based on phenomena, mechanisms, and kinetics
  • SpeakerYoshiyuki Shirasaka
  • Laboratory of Pharmaceutics, Showa Pharmaceutical University
  • SY14-2Development and In Silico Validation of a Novel Method for Evaluating the Oral Absorption of P-gp Substrate Macrocyclic Peptides
  • SpeakerRyo Tamura
  • Non Clinical Research Dept., Translational Research Division, Chugai Pharmaceutical Co., Ltd.
  • SY14-3Oral formulation strategies for medium-size drugs: From the perspective of physicochemical properties
  • SpeakerKunikazu Moribe
  • Laboratory of Pharmaceutical Technology, Graduate School of Pharmaceutical Sciences, Chiba University
  • SY14-4Formulation and kinetic research for oral mid-size molecule in drug discovery
  • SpeakerTakashi Nozawa
  • Formulation & ADME, Oncology Research, Astellas Pharma Inc.
  • Panel Discussion

JSSX Special Symposium

November 17 (Tue.) 14:15-17:15 Room A (2F Leo Esaki Main Convention Hall)

Advances in DDI evaluations: Recent Trends from Pre-clinical Studies to Regulatory Submissions

  • ChairChie Emoto
  • Translational Research Division, Chugai Pharmaceutical Co., Ltd.
  • ChairR. Scott Obach（Pfizer, Inc.）
  • SSY-1Special Issue Overview: Advances in DDI Evaluation - Perspectives and Case Studies Across Academia, Industry, and Regulators-
  • SpeakerChie Emoto
  • Translational Research Division, Chugai Pharmaceutical Co., Ltd.
  • SSY-2Latest Improvements for In Vitro Metabolism Studies to Address Drug-Drug Interactions
  • SpeakerR. Scott Obach
  • Pfizer, Inc.
  • SSY-3Evaluation of hepatic CYP3A4 induction using hu-PXB mice (Tentative)
  • SpeakerHaruka Tsutsui
  • Chugai Pharmaceutical Co., Ltd.
  • SSY-4UDP-Glucuronosyl transferase mediated drug-drug interactions: An Industry perspective on recommended in vitro studies
  • SpeakerDavid M. Stresser
  • Quantitative, Translational & ADME Sciences/QTAS, AbbVie Inc.
  • SSY-5Lessons Learned from Using Coproporphyrin I for Regulatory Submission: Insights from the Ensitrelvir Case and Beyond
  • SpeakerRyosuke Watari
  • Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd.
  • SSY-6Advances and challenges for drug interaction evaluation - Perspectives on the ICH M12 guideline
  • SpeakerYuya Suzuki
  • Pharmaceuticals and Medical Devices Agency
  • SSY-7Managing Implementation of Next Generation MIDD: Integration via Model Master File
  • SpeakerAmin Rostami
  • University of Manchester & Certara Inc, UK

Organizering Committee Symposium

November 19 (Thu.) 13:30-15:30 Room A (2F Leo Esaki Main Convention Hall)

The Cutting Edge of Human Prediction and Risk Assessment in ADMET Sciences: Challenging by Nonclinical Approaches and Methodologies

  • ChairTakafumi Komori
  • Biopharmaceutical Assessment, Deep Human Biology Learning, Eisai Co., Ltd.
  • ChairToru Usui
  • Preclinical Research Unit, Sumitomo Pharma Co., Ltd.
  • OSY-1TBD
  • SpeakerTomoya Sameshima
  • Preclinical and Translational Sciences, Takeda Pharmaceutical Company Limited
  • OSY-2Advances in Toxicity and Translational Research Using Human Tissues (Tentative)
  • SpeakerFoivos-Filippos Tsokanos
  • Pharmacokinetics and Pharmacodynamics Research Laboratories, Daiichi Sankyo Co. Ltd.
  • OSY-3TBD
  • SpeakerShotaro Uehara
  • Department of Research for Humanized Model, Central Institute for Experimental Medicine and Life Science
  • OSY-4Extrapolation of Drug Absorption and Gastrointestinal Toxicity to Humans Based on Intestinal Stem Cell-Derived Models (Tentative)
  • SpeakerHiroyuki Kusuhara
  • Graduate School of Pharmaceutical Sciences, The University of Tokyo

Asia Joint Symposium

November 18 (Wed.) 9:30-12:00 Room D (1F Conference Room 101)

  • ChairKazuya Maeda
  • Laboratory of Pharmaceutics, School of Pharmacy, Kitasato University
  • ASY-1　
  • SpeakerSiwanon Jirawatnotai
  • Department of Pharmacology and SiCORE for Systems Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University
  • ASY-2　
  • SpeakerYoung-Hee Choi
  • College of the Pharmacy, Dongguk University
  • ASY-3　
  • SpeakerShashyendra Singh Gautam
  • Biocon Bristol Myers Squibb Research & Development Center
  • ASY-4Industry perspective for evaluating CYP450 Induction: Challenges and Solutions in PCC/IND/NDA
  • SpeakerZhuohan Hu
  • Research Institute for Liver Diseases (Shanghai) Co. Ltd., Chinese Industry Society for Study of Xenobiotics (CBIITA-SSX)
  • ASY-5　
  • SpeakerShigeki Aoki
  • Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University

The Predoctoral Researcher-Initiative Session (PRIS) 2026

November 19 (Thu.) 9:30-12:00 Room E (1F Conference Room 102)

  • ChairYohei Ohto
  • Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo
  • ChairKeiichiro Nakamura
  • Laboratory of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kitasato University
  • ChairShogo Yasuda
  • Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University
  • PSY-ELInvestigation of the Role of Mucin in Drug Absorption and Its Molecular Basis (Tentative)
  • SpeakerHisanao Kishimoto
  • Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • PSY-1Model-Dependent Variation in Pharmacokinetics after Intraperitoneal Administration in Peritoneal Dissemination Mouse Models
  • SpeakerMisaki Ishida
  • Laboratory of DDS Design and Drug Disposition, Graduate School of Pharmaceutical Sciences, Chiba University
  • PSY-2Systematic Detection of Drug Interactions Involving Inhibition of CYP3A Using Adverse Event Reporting Database
  • SpeakerHana Kumemura
  • Laboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University
  • PSY-3Elucidating Organ Crosstalk Mediated by OAT2/SLC22A7
  • SpeakerKeisuke Sato
  • Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences
  • PSY-4Cross-species assessment of gastrointestinal toxicity potentially caused by impaired epithelial function development using animal and small intestinal organoids
  • SpeakerMana Namai
  • Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo
  • PSY-5Improved prediction of BCRP-mediated biliary clearance by incorporating hepatic cytosolic protein-facilitated transport into relative expression factor approach
  • SpeakerShotaro Yoshino
  • Laboratory of Molecular Pharmacotherapeutics, Faculty of Pharmacy, Kanazawa University